Athenex, Inc. (NASDAQ:ATNX) Q3 2019 Earnings Conference Call - Final Transcript
Nov 07, 2019 • 08:00 am ET
Greetings and welcome to the Athenex Inc. Third Quarter 2019 Earnings Call. A question-and-answer session will follow the formal presentation. [Operator Instructions]
I would now like to turn the conference over to your host Mr. Tim McCarthy with LifeSci Advisors. Please go ahead sir.
Good morning and thank you for joining our conference call as we provide an update on Athenex's business as well as a review of financial results for the third quarter of 2019. The news release detailing the third quarter results crossed the wire earlier this morning and is available on the company's website. A replay of this call will also be archived on the company website. During the course of this conference call the company will make projections or forward-looking statements regarding future events including statements about financial and clinical milestones anticipated in fiscal year 2019 and beyond. We encourage you to review the company's past and future filings with the SEC which identify specific factors that may cause the actual results or events to differ materially from those described in the forward-looking statements. You can find our SEC filings in the EDGAR database at sec.gov or in the Investor Relations section at our website at athenex.com. This morning we are joined by Dr. Johnson Lau Chief Executive Officer; Mr. Jeff Yordan Chief Operating Officer; Dr. Rudolf Kwan Chief Medical Officer; Mr. Randoll Sze Chief Financial Officer; and several other executives who will be available to answer questions after the prepared remarks.
With that I'll turn the call over to Johnson for introductory comments.
Johnson Y.N. Lau
Thank you Tim. Hello and welcome. We have continued to make strong progress across the board bringing us closer to becoming a fully integrated global pharmaceutical company. For the second time this year we are pleased to be raising full-year product sales guidance for 2019. We have several major catalyst upcoming including an oral presentation of oral practice. So in secular data at the upcoming San Antonio breast cancer meeting into anticipated and the findings in early 2020, which we expect to follow with record findings in additional global markets. We're also in a very strong position to advise multiple, potentially successful therapies in the future. We have been strategic in building our operations and mentioned our resources to maximize the potential commercial opportunity of drop Kennedy's in development is our broader pipeline continues to advance. We're looking beyond current indications and for ways to get the best labels and marketing outcomes for our products. As we prepare to market our first proprietary oncology product oral paclitaxel and encequidar we are making significant progress to expand and optimize our commercial infrastructure. We expect to be well prepared to make a significant impact with this product in literally once it's approved.
As our Chief Operating Officer Mr. Jeff Yordon will discuss a major part of our ongoing commercial preparation as it continues raising the profile of our new Athenex oncology brand and become a recognized commercial player with differentiated products with target -- that